Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Equity Average (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of Equity Average data on record, last reported at $33.3 million in Q4 2025.

  • For Q4 2025, Equity Average fell 53.49% year-over-year to $33.3 million; the TTM value through Dec 2025 reached $33.3 million, down 53.49%, while the annual FY2025 figure was $61.5 million, 12.45% down from the prior year.
  • Equity Average reached $33.3 million in Q4 2025 per LCTX's latest filing, down from $34.6 million in the prior quarter.
  • Across five years, Equity Average topped out at $121.6 million in Q3 2021 and bottomed at $33.3 million in Q4 2025.
  • Average Equity Average over 5 years is $75.9 million, with a median of $70.5 million recorded in 2023.
  • Peak YoY movement for Equity Average: rose 29.44% in 2021, then tumbled 53.49% in 2025.
  • A 5-year view of Equity Average shows it stood at $121.6 million in 2021, then tumbled by 38.53% to $74.7 million in 2022, then decreased by 13.92% to $64.3 million in 2023, then increased by 11.26% to $71.6 million in 2024, then crashed by 53.49% to $33.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $33.3 million in Q4 2025, $34.6 million in Q3 2025, and $62.4 million in Q2 2025.